Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

#160; Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries.  The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets.   Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products. 

Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories.  Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.  

Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually.  Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release.  For instance, any statements in this press release concerning prospe
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DEERFIELD, Ill. , Aug. 21, 2014 /PRNewswire/ ... reports Baxter International Inc. today announced positive results ... BAX 855, an investigational, extended half-life recombinant factor ... ADVATE [Antihemophilic Factor (Recombinant)], which met its primary ... the prophylaxis arm compared to the on-demand arm. ...
(Date:8/21/2014)... Canadian Epilepsy Alliance (CEA) is thrilled to announce the launch ... the most common neurological disorder in Canada ... tells a fictional story based on the experiences of 14-year-old ... "Despite the fact that epilepsy affects 1 ... lack of awareness out there," says Gail Dempsey , ...
(Date:8/21/2014)... -- Seventy-one percent of Americans believe the abuse of strong prescription ... and safety issue in the United States ... Repass & Partners, a Cincinnati based ... of the prescription medication abuse problem and the need for ... situation facing our country," Rex Repass , CEO of ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... (Nasdaq: CADX ) today announced that it has ... common stock at a price to the public of $3.75 ... shares, after deducting the underwriting discounts and commissions and estimated ... has granted the underwriters for the offering a 30-day option ...
... 15, 2011 Reportlinker.com announces that a ... its catalogue: The Outlook ... http://www.reportlinker.com/p0617406/The-Outlook-for-Pharmaceuticals-in-North-East-Asia ... pharmaceutical markets that present immense potential for ...
Cached Medicine Technology:Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock 3The Outlook for Pharmaceuticals in North East Asia 2The Outlook for Pharmaceuticals in North East Asia 3The Outlook for Pharmaceuticals in North East Asia 4
(Date:8/22/2014)... Princeton, Indiana (PRWEB) August 22, 2014 ... because Toyota Indiana is on the grow ... add 300 jobs by summer 2016 to boost production ... expansion will bring Toyota Indiana’s overall investment to $4 ... in North America while providing additional flexibility to adjust ...
(Date:8/22/2014)... Medicine team has found that targeted automated alerts ... infections in hospital patients with urinary catheters. In ... simplified, the rate of improvement dramatically increased. , ... need urinary catheters in the first place and ... catheters that have not been removed within a ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Worth, FL (PRWEB) August 22, 2014 ... addiction treatment facility in Lantana, FL, recently launched ... those just looking for information can now find ... Millennium’s new website just went live at the ... know about the facility can be found on ...
(Date:8/22/2014)... 2014 Beat Eczema , Susan ... use natural methods to completely cure the eczema symptoms ... of Shane Michaels, prompting an investigative review. , ... skin, it can still be extremely debilitating and life-altering ... intense itching and pain that it causes on the ...
Breaking Medicine News(10 mins):Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... annually in Thailand is an ongoing challenge for ... to Somchai Pinyopornpaitch, deputy director-general of the Department ... several years despite health officials' efforts. TB incidence ... with 90,000 new cases annually, and the treatment ...
... the go-ahead to the new cosmetic filler, Radiesse, to ... in patients with AIDS or HIV. This calcium based ... collagen. ,To ascertain the potential benefits of ... HIV patients suffering facial lipoatrophy. The patients were given ...
... ‘Mindfulness’ is now being taught to Queensland women with eating ... women who struggle with binge eating and bulimia. It is ... emotions that trigger their binges. ,Unlike many ... and controlling eating and more on providing freedom from negative ...
... as a simple equation; more guns, more murders. ... Harvard School of Public Health came out with results of ... firearms is a hot topic in US, where the case ... three US households owns a gun,according to current data. ...
... on the surprise findings of a study appearing in the ... that scientists have discovered histamine,// the inflammatory compound released during ... ,They say that histamine can be produced ... Blood Cells (WBC) that is the major component of pus. ...
... box that is where most of our chores end up in. ... tried to makes sense out// of why we procrastinate, in a ... study took ten years instead of five, Steel has put up ... (U) = Expectation of Success (E) x Value of Completion (V) ...
Cached Medicine News:Health News:WBC in Lung Produces Histamine: Study 2Health News:WBC in Lung Produces Histamine: Study 3Health News:Read This Now Not Later! 2
... utilize Linvatecs exclusive Shockflex prism system to ... Using the latest technology, our 3CCD Camera ... and brightness. The Camera Heads are available ... configured with a number of optical couplers ...
... an integrated coupler can be steam sterilized using ... it is cool to the touch and ready ... Smarthead technology allowing each head to store procedure ... head has been used is displayed on the ...
... invasive surgery is founded on superior medical ... of 3-Chip cameras, 1-Chip cameras, Light sources, ... your demanding needs., ,Superior resolution and ... our 3-Chip cameras, and are the benchmark ...
... high-resolution 1-Chip Camera System provides easy-to-use features, ... small scope. The camera head construction is ... ,Complete 1-Chip Camera System for Microscopic Application, ... Camera Control Unit (CCU) with power cord ...
Medicine Products: